Tavotek Biotherapeutics Announces Completion of Round B Financing with $35 Million

LOWER GWYNEDD,Penn.,Nov. 19,2021 -- Tavotek Biotherapeutics,a fast-growing biotech company,announcesithasraised $35Min Round B financing. CS Capital,a leading private equity fund manager in China,led thisfinance round followed by FontusCapital. This roundof financing will be used to accelerate the Phase 1 clinical developmentof several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on itsTavoPrecise antibody platform for various immune-related disorders. In addition,the funding will also be used to accelerate the CMC and IND development of multiple other oncology pipelines and the development of the company's multicyclic intracellular peptide (MIP) programs.

Tavotek Biotherapeutics,established in early2019,is committed to using innovation to improvethe well-beingof patients with unmet medical needs. The company has two R&D centers: one inLower Gwynedd,Pennsylvaniaand another in Suzhou,China. The core team members have decades of successful drug development experiences at multinational pharmaceutical firms (Johnson & Johnson,Abbott/Abbvie,GlaxoSmithKline and Eli Lilly) which include many blockbuster drugs with annual sales of more than$1 billion.

Tavotek's research platformsare built uponthree breakthroughtechnologies:TavoSelect(an innovative Phage Display Library that generates conformational selective human full-length and single domain antibodies);TavoPrecise(a differentiatedengineering platformfor next generation tissue-specific biologics); andTavoMIP(a multicyclic peptide platformthat makes undruggabletargetsmore accessible).With thenewinfusionof capital,Tavotek is developing novel biologics targeting oncology and autoimmune diseases for patients. The company plans to bring multiple innovative antibodies into human clinical trials in 2022.

About Tavotek

Tavotek is a biopharmaceutical company focused on discovering,acquiring,developing,and commercializing medicines for patients suffering from debilitating diseases with significant unmet medical needs. Tavotek has a rich pipeline of product candidates at various stages of development for cancer,autoimmune conditions,and inflammatory diseases. For more information,please visitwww.tavotek.com.

Tavotek Contact:

Vicky Wu,External Affairs

Email:vicky.wu@tavotek.com

Isa Fung,Investors and Media

Email:info@tavotek.com

View original content:https://www.prnewswire.com/news-releases/tavotek-biotherapeutics-announces-completion-of-round-b-financing-with-35-million-301426583.html